Johnson & Johnson

Working to Change the Trajectory of Lung Cancer

At Johnson & Johnson, we are focused on tackling lung cancer from every angle and are driven by our passion to help patients.

The Impact of Lung Cancer[1]

Highest global death rate of all cancers

2nd most common cancer globally, behind only breast cancer

On average, **5,000 lives are claimed every day**

Lung cancer is difficult to diagnose early.

↓ It starts growing very **deep in the lung**[2]

↓ Symptoms only start when it has grown significantly and **spread outside the lung**[2]

Early diagnosis is key.

↓ Earlier diagnosis could mean easier treatment and potentially cure[3]

↓ But **most people are diagnosed at advanced stages,** when treatment options are limited[3]

Screening is critical for those at increased risk.

↓ Regular **low-dose CT (LDCT) scans are the most important step** at-risk people can take toward early detection[2]

↓ Risk factors can include smoking, genetic susceptibility, poor diet, occupational exposures, and air pollution[4]

Anyone can get lung cancer.

↓ Up to **25% of lung cancers worldwide occur in people who have never smoked**[5]

↓ Stigma or blame are common, preventing timely screening and treatment[6]

A multifaceted disease requires a multidisciplinary approach.

Innovation at Johnson & Johnson has helped pave the way in oncology for more than 30 years. We are working holistically across the company to drive early detection, treatment and ongoing research and development **to help make a difference in the lives of millions of people.**

Maintaining health and creating a sense of hope for all people impacted by lung cancer are what drive us. **Together, we aim to change the trajectory of lung cancer.**

REFERENCES

[1] National Institutes of Health. CT screening significantly reduces lung cancer mortality. Available at: https://www.nih.gov/news-events/nih-research-matters/ct-screening-significantly-reduces-lung-cancer-mortality. Last accessed: July 2022.

[2] International Agency for Research on Cancer. GLOBOCAN 2020: Lung. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Last accessed: July 2022.

[3] Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers – A review. Eur J Cancer. 2012;48(12): 1299-1311. https://www.sciencedirect.com/science/article/abs/pii/S0959804912002523. Last accessed: July 2022.

[4] Scott N, Crane M, Lafontaine M, et al. Stigma as a barrier to diagnosis of lung cancer: patient and general practitioner perspectives. Prim Health Care Res Dev. 2015;16(6):618-622. https://www.cambridge.org/core/journals/primary-health-care-research-and-development/article/stigma-as-a-barrier-to-diagnosis-of-lung-cancer-patient-and-general-practitioner-perspectives/00DCD12CBBDCBC4517DCD678924BC277. Last accessed: July 2022

[5] National Cancer Institute. SEER cancer stat facts: Lung and bronchus cancer. Available at: https://seer.cancer.gov/statfacts/html/lungb.html. Last accessed: July 2022.

[6] Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889-902. https://erj.ersjournals.com/content/48/3/889. Last accessed: July 2022.